These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 24819055)
1. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres. Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055 [TBL] [Abstract][Full Text] [Related]
2. Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ Wagemans MEHM; Braat AJAT; van Rooij R; Smits MLJ; Bruijnen RCG; Prince JF; Bol GM; de Jong HWAM; Lam MGEH Cardiovasc Intervent Radiol; 2024 Apr; 47(4):443-450. PubMed ID: 38326577 [TBL] [Abstract][Full Text] [Related]
3. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy. Song YS; Paeng JC; Kim HC; Chung JW; Cheon GJ; Chung JK; Lee DS; Kang KW Medicine (Baltimore); 2015 Jun; 94(23):e945. PubMed ID: 26061323 [TBL] [Abstract][Full Text] [Related]
4. The superior predictive value of Smits MLJ; Dassen MG; Prince JF; Braat AJAT; Beijst C; Bruijnen RCG; de Jong HWAM; Lam MGEH Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):798-806. PubMed ID: 31399801 [TBL] [Abstract][Full Text] [Related]
5. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. Wondergem M; Smits ML; Elschot M; de Jong HW; Verkooijen HM; van den Bosch MA; Nijsen JF; Lam MG J Nucl Med; 2013 Aug; 54(8):1294-301. PubMed ID: 23749996 [TBL] [Abstract][Full Text] [Related]
6. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres. Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477 [TBL] [Abstract][Full Text] [Related]
7. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing Noipinit N; Sukprakun C; Siricharoen P; Khamwan K Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421 [TBL] [Abstract][Full Text] [Related]
8. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related]
9. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT. Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581 [TBL] [Abstract][Full Text] [Related]
10. Calculation of lung mean dose and quantification of error for Lopez B; Mahvash A; Lam MGEH; Kappadath SC Med Phys; 2019 Sep; 46(9):3929-3940. PubMed ID: 31063600 [TBL] [Abstract][Full Text] [Related]
11. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137 [TBL] [Abstract][Full Text] [Related]
14. Hepatopulmonary Shunt Ratio Verification Model for Transarterial Radioembolization. Yeyin N; Kesmezacar FF; Tunçman D; Demir Ö; Uslu-Beşli L; Günay O; Demir M Curr Radiopharm; 2024; 17(3):276-284. PubMed ID: 38288829 [TBL] [Abstract][Full Text] [Related]
15. Feasibility of imaging Kunnen B; Dietze MMA; Braat AJAT; Lam MGEH; Viergever MA; de Jong HWAM Med Phys; 2020 Mar; 47(3):1105-1114. PubMed ID: 31855282 [TBL] [Abstract][Full Text] [Related]
16. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830 [TBL] [Abstract][Full Text] [Related]
17. The value of Allred JD; Niedbala J; Mikell JK; Owen D; Frey KA; Dewaraja YK EJNMMI Res; 2018 Jun; 8(1):50. PubMed ID: 29904808 [TBL] [Abstract][Full Text] [Related]
18. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460 [No Abstract] [Full Text] [Related]
19. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479 [TBL] [Abstract][Full Text] [Related]
20. High quality imaging and dosimetry for yttrium-90 ( Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]